In vitro activity of manogepix against Candida spp. displaying elevated echinocandin MIC results
Antimicrobial Agents and Chemotherapy · 10.11.2026
DOI: 10.1128/aac.00859-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, online erschienen am 10.11.2026. Verfasst von Marisa L Winkler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fosmanogepix is the prodrug of manogepix, an antifungal agent with a novel mechanism of action targeting the cell wall anchoring protein Gwt1. Fosmanogepix is currently in a Phase 3 clinical trial for the treatment of candidemia and invasive candidiasis (CIC). Echinocandins are first-line recommendations for empiric treatment of CIC, but resistance rates are rising, particularly in Candida glabrata . Given its unique mechanism of action, manogepix might retain activity against Candida spp. isolates that are non-susceptible to echinocandins, although supporting data are limited. Here, we collected 129 Candida spp. isolates from worldwide surveillance testing between 2017 and 2024 that were either resistant or non-wild type (WT) to ≥1 echinocandin when applying the Clinical and Laboratory Standards Institute breakpoints or epidemiological cutoff values. Isolates included 74 C. glabrata , 19 C. albicans , 14 C. auris , 14 C. tropicalis , 3 C. dubliniensis , 2 C. guilliermondii , and 1 each of C. krusei , C. lusitaniae , and C. parapsilosis . Sequencing of the gene encoding the echinocandin target was performed in all isolates and 75/129 (58.1%) had ≥1 alteration in a hotspot region of FKS1 and/or FKS2. Manogepix maintained low minimum inhibitory concentrations (MICs) across all isolates with only one C. auris isolate with a MIC above the prior WT-upper limit-defined value of 0.03 mg/L. This isolate had an alteration in Tac1B but wild-type Gwt1. All isolates were WT for amphotericin B and fluconazole resistance varied depending on species from 0% to 100%. The continued clinical development of manogepix for the treatment of CIC is warranted, including against resistant isolates based on these data.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA.
ORCID-Profile: Marisa L Winkler, John H Kimbrough, Paul Rhomberg, Mariana Castanheira
Zitieren
APA
Winkler, M. L., Kimbrough, J. H., Edeker, S., Klauer, A., Karr, M. H., Rhomberg, P., & Castanheira, M. (2026). In vitro activity of manogepix against Candida spp. displaying elevated echinocandin MIC results. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00859-26
Vancouver
Winkler ML, Kimbrough JH, Edeker S, Klauer A, Karr MH, Rhomberg P, et al. In vitro activity of manogepix against Candida spp. displaying elevated echinocandin MIC results. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00859-26
BibTeX
@article{Winkler2026,
author = {Winkler, Marisa L and Kimbrough, John H and Edeker, Samuel and Klauer, Abby and Karr, Maura H and Rhomberg, Paul and Castanheira, Mariana},
title = {In vitro activity of manogepix against Candida spp. displaying elevated echinocandin MIC results},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00859-26}
}
EUVIMED